ERVW-1 and dengue disease: Two chimeric live-attenuated vaccines, based on either dengue serotype 4 (rWN/DEN4Δ30) or YFV-17D (ChimeriVax-WN) backbones expressing WNV prM/Env proteins, have been tested in humans [10–13].